Stockreport

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma [Yahoo! F...

Delcath Systems, Inc.  (DCTH) 
US:NASDAQ Investor Relations: delcath.com/investors
PDF company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from subgroup analyses of the phase 3 FOCUS study. T [Read more]